Michael T. Ouellette has over 17 years of experience in small molecule drug discovery. He currently works as an investigator and group leader at GlaxoSmithKline, where he mentors a group of scientists. Prior to his current role, Ouellette held positions with increasing responsibility at several pharmaceutical companies, gaining expertise in high-throughput screening, assay development, hit identification and qualification. He has contributed to the development of several clinical candidates and platforms. Ouellette also has strong leadership, project management, and analytical skills.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
2nd CRISPR Congress Boston, 23-25 February 2016 Diane McKenna
The 2nd Annual CRISPR Congress will enhance the basic research, drug discovery and therapeutic applications of CRISPR technology by overcoming key specificity, efficiency and delivery challenges needed to improve the precise editing and repair of the genome.
Multi-trait modeling in polygenic scores, journal club talk at Debora Marks labYosuke Tanigawa
I was invited to give a presentation at the Journal Club meeting at Debora Marks's lab. Here we have the slides for the presentation.
Please visit my website to learn more about this presentation: https://yosuketanigawa.com/talks/2022-01-28-jclub-Marks-lab
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryJean-Claude Bradley
Mel Reichman, senior investigator and director of the LIMR Chemical Genomics Center at the Lankenau Institute for Medical Research presents at the chemistry department at Drexel University on November 12, 2009.
Modern drug discovery by high-throughput screening (HTS) begins with testing hundreds of thousands of compounds in biological assays. The confirmed hit rate for typical HTS is less than 0.5%; therefore, 99.5% of the costs of HTS are for generating null data. Orthogonal convolution of compound libraries (OCL) is 500% more efficient than present HTS practice. The OCL method combines 10 compounds per well. An advantage of this method is that each compound is represented twice in two separately arrayed pools. The potential for the approach to better enable academic centers of excellence to validate medicinally relevant biological targets is discussed.
BOUNCER: A Privacy-aware Query Processing Over Federations of RDF DatasetsKemele M. Endris
Data provides the basis for emerging scientific and interdisciplinary data-centric applications with the potential of improving the quality of life for the citizens. However, effective data-centric applications demand data management techniques able to process a large volume of data which may include sensitive data, e.g., financial transactions, medical procedures, or personal data. Managing sensitive data requires the enforcement of privacy and access control regulations, particularly, during the execution of queries against datasets that include sensitive and non-sensitive data. In this paper, we tackle the problem of enforcing privacy regulations during query processing, and propose BOUNCER, a privacy-aware query engine over federations of RDF datasets. BOUNCER allows for the description of RDF datasets in terms of RDF molecule templates, i.e., abstract descriptions of the properties of the entities in an RDF dataset and their privacy regulations. Furthermore, BOUNCER implements query decomposition and optimization techniques able to identify query plans over RDF datasets that not only contain the relevant entities to answer a query, but that are also regulated by policies that allow for accessing these relevant entities. We empirically evaluate the effectiveness of the BOUNCER privacy-aware techniques over state-of-the-art benchmarks of RDF datasets. The observed results suggest that BOUNCER can effectively enforce access control regulations at different granularity without impacting the performance of query processing.
Next-generation sequencing has enabled clinicians and researchers alike to identify novel genetic variants associated with rare Mendelian Diseases across the human genome. To help enable researchers and clinicians understand the role of CNVs in human health and disease, Golden Helix has integrated a specialized NGS-based CNV caller capable of detecting deletion and duplication events as small as single-exons and as large as whole chromosome aneuploidy events. In this webcast, we will present our workflows that integrates the NGS-based CNV caller into SVS.
Multi-trait modeling in polygenic scores, journal club talk at Debora Marks labYosuke Tanigawa
I was invited to give a presentation at the Journal Club meeting at Debora Marks's lab. Here we have the slides for the presentation.
Please visit my website to learn more about this presentation: https://yosuketanigawa.com/talks/2022-01-28-jclub-Marks-lab
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryJean-Claude Bradley
Mel Reichman, senior investigator and director of the LIMR Chemical Genomics Center at the Lankenau Institute for Medical Research presents at the chemistry department at Drexel University on November 12, 2009.
Modern drug discovery by high-throughput screening (HTS) begins with testing hundreds of thousands of compounds in biological assays. The confirmed hit rate for typical HTS is less than 0.5%; therefore, 99.5% of the costs of HTS are for generating null data. Orthogonal convolution of compound libraries (OCL) is 500% more efficient than present HTS practice. The OCL method combines 10 compounds per well. An advantage of this method is that each compound is represented twice in two separately arrayed pools. The potential for the approach to better enable academic centers of excellence to validate medicinally relevant biological targets is discussed.
BOUNCER: A Privacy-aware Query Processing Over Federations of RDF DatasetsKemele M. Endris
Data provides the basis for emerging scientific and interdisciplinary data-centric applications with the potential of improving the quality of life for the citizens. However, effective data-centric applications demand data management techniques able to process a large volume of data which may include sensitive data, e.g., financial transactions, medical procedures, or personal data. Managing sensitive data requires the enforcement of privacy and access control regulations, particularly, during the execution of queries against datasets that include sensitive and non-sensitive data. In this paper, we tackle the problem of enforcing privacy regulations during query processing, and propose BOUNCER, a privacy-aware query engine over federations of RDF datasets. BOUNCER allows for the description of RDF datasets in terms of RDF molecule templates, i.e., abstract descriptions of the properties of the entities in an RDF dataset and their privacy regulations. Furthermore, BOUNCER implements query decomposition and optimization techniques able to identify query plans over RDF datasets that not only contain the relevant entities to answer a query, but that are also regulated by policies that allow for accessing these relevant entities. We empirically evaluate the effectiveness of the BOUNCER privacy-aware techniques over state-of-the-art benchmarks of RDF datasets. The observed results suggest that BOUNCER can effectively enforce access control regulations at different granularity without impacting the performance of query processing.
Next-generation sequencing has enabled clinicians and researchers alike to identify novel genetic variants associated with rare Mendelian Diseases across the human genome. To help enable researchers and clinicians understand the role of CNVs in human health and disease, Golden Helix has integrated a specialized NGS-based CNV caller capable of detecting deletion and duplication events as small as single-exons and as large as whole chromosome aneuploidy events. In this webcast, we will present our workflows that integrates the NGS-based CNV caller into SVS.
Discovery on Target 2014 - The Industry's Preeminent Event on Novel Drug TargetsJaime Hodges
Cambridge Healthtech Institute's 12th Annual Discovery on Target will showcase current and emerging “hot” targets for the pharmaceutical industry, October 8 – 10, 2014 in Boston, MA. Spanning three days, the meeting will bring together more than 900 global attendees, including scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production. The 2014 event will offer 200+ scientific presentations across 14 conference tracks, 1 Symposium and 15 conference short courses, 40+ interactive breakout discussion groups, an exhibit hall of 40+ companies, and dedicated poster viewing and networking sessions.
1. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
M I C H A E L T . O U E L L E T T E
619 East Reeceville Rd ▪ Downingtown, PA 19335
BIOGRAPHY
Accomplished scientist with 17 years experience in small molecule drug discovery. I have a
versatile set of skills in the laboratory while concurrently managing other scientists,
demonstrating leadership at the project level, and capable of influencing scientific strategy.
03/2006 – present SPMB - GlaxoSmithKline Collegeville, PA
Investigator, Group Leader
Mentor group of 5 scientists working side-by-side with them, providing scientific oversight and
technical guidance. Continually striving to build a team that is extremely versatile and can support
all areas within SPMB
Manage staff development through objective setting, tracking performance and providing
guidance to create a structured development program
Demonstrated ability to influence scientific strategy of numerous concurrent projects
serving as project co-leader or individual contributor. Examples of recent programs include
PLCλ2, cccDNA, Matriptase-2, RIPK1, RIPK2
Demonstrated ability to effectively engage and work across a matrix to accomplish program
objectives and solve problems
Small molecule drug discovery experience across a broad range of target classes: Kinases, GPCR’s,
Pattern Recognition Receptors, phosholipases, transcription factors, proteases, antiviral targets,
hematological targets
Individually contribute to program objectives by utilizing broad technical expertise across all
functions of SPMB: Assay development, hit identification, profiling, hit qualification, cell biology,
biochemistry, externalization
Contributed to candidate selection of more than a half dozen molecules
Developed and performed series of ELT experiments that led to development of clinical asset
GSK2982772, autoimmune therapy
Key leader in establishment and evolution of multiple platforms including ELT, qRT-PCR,
centrifugal microtiter plate evacuation, HTS
Currently working to establish biopharm functional cell assay screening platform within SPMB
5 years experience in portfolio management, project prioritization, and resource allocation
HTS Manager: Managed 1/3 of HTS portfolio across multiple DPU/TA’s: Managed flow of HTS
campaigns through screening platforms, ensure transparency of portfolio & status, define and
validate hit identification and triage strategy, manage high throughput screen process, ensure highest
quality data, analyze & communicate data, and track campaign outcomes
Expertise in integrated hit discovery modalities including HTS, focus screening, fragment
screening, and ELT. Influence project strategy based on biology and project objectives
Strong analytical skills and ability to work with large datasets: identify patterns, create
fascicle data visualizations, define context, enable data driven decisions
Serve as scientific mentor to scientists outside of my direct reports as well as mentoring two co-
op students
Business Expert User (BEU) involved in the enhancement of multiple MDR sponsored IT
assets including ABASE XE, DART, DRAM and MOSAIC
2. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
09/2005 – 03/2006 Molecular Devices Corporation Downingtown, PA
Field Applications Scientist
Supported the development of high-content screening imaging systems
Provided training and field support for Transfluor and ImageXpress Micro to potential and
established Molecular Devices customers
Created User Manual for Transfluor technology
Responsible for internal training of sales staff regarding the ImageXpress Ultra high-content confocal
imaging system
03/2002 – 09/2005 Xsira Pharmaceuticals Morrisville, NC
Research Associate III – Lead Generation and Progression
Conducted high throughput screening campaigns to discover compounds that modulate G Protein-
Coupled Receptor desensitization
Involved in the development, validation, and automation of Transfluor®, a universal cell-based
imaging technology for G-protein Coupled Receptors
Developed and optimized cell-based and biochemical assays to support internal drug discovery
programs
Researched, acquired, implemented, and oversaw all HTS automation
Co-developed a process of scaling up and freezing back large numbers of screen ready cells (2E9) at
high density (40E6 cells/mL)
Developed storage solution and distribution paradigm for a compound repository of >800,000
chemical compounds
11/1999 – 03/2002 Neurogen Corporation Branford, CT
Research Associate I
Screened G-Protein Coupled Receptor and ion channel targets in Ca2+ flux functional assays (FLIPR)
and binding assays
Provided data to drive Lead-op and chemical optimization efforts
Acted as contact person for the programming, quality control, and service of automated equipment
EDUCATION
09/1995 – 05/1999 University of New Hampshire Durham, NH
Bachelor of Science in Microbiology; Summa Cum Laude
Investigated the role of cytokines in the infection of alveolar macrophages by Legionella pneumophila
Laboratory animal handling, dosing, and tissue harvesting
Cell culture and sterile technique.
COMPUTER SKILLS
SpotFire, SQL, Microsoft Office – strong Excel skills, eLNB, LotusNotes, ActivityBase, INCA, OR&M,
Discovery Explorer, JMP, GraphPad PRISM, Samuari, DART, DRAM, ELT Enterprise application, BI
PUBLICATIONS
Xie W, Silvers R, Ouellette M, Wu Z, Lu Q, Li H, Gallagher K, Johnshon K, Montoute M. 2016.
A Luciferase Reporter Gene System for High-Throughput Screening of γ-Globin Gene Activators.
In: High Throughput Screening: Methods & Protocols. Vol. 1439. New York: Springer Science +
Business Media. p. 207-226.
Harris P, King B, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti C, Cox J, Dare L, Dong
X, Finger J, Grady L, Hoffman S, Jeong J, Kang J, Kasparkova V, Lakdawala A, Lehr R, McNulty D,
3. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
Nagilla R, Ouellette M, Pao C, Rendina A, Schaeffer M, Summerfield J, Swift B, Totoritis R, Ward
P, Zhang A, Zhang D, Marquis R, Bertin J, Gough J (2016) DNA-Encoded Library Screening
Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting
Protein 1 Kinase Inhibitors. Journal of Medicinal Chemistry, 59(5): 2163-78
Haile P, Votta B, Marquis R, Bury M, Mehlmann J, Singhaus R, Charnley A, Lakdawala A, Convery
M, Lipshutz D, Desai B, Swift B, Capriotti C, Berger S, Mahajan M, Reilly M, Rivera E, Sun H,
Nagilla R, Beal A, Finger J, Cook M, King B, Ouellette M, Totoritis R, Pierdomenico M, Negroni
A, Stronati L, Cucchiara S, Ziokowski B, Vossenkamper A, MacDonald T, Gough P, Bertin J,
Casillas L (2016) The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-
N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of
RIP2 Kinase. Journal of Medicinal Chemistry, 59(10): 4867-80
Berger SB, Harris P, Nagilla R, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, Capriotti
C, Ouellette M, King BW, Wisnoski D, Cox J, Reilly M, Marquis RW, Bertin J, Gough PJ (2015)
Characterization of GSK’963: A Structurally Distinct, Potent and Selective Inhibitor of RIP1 Kinase.
Cell Death Discovery, 15009(1).
Charnley A, Convery M, Lakdawala A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R,
Schwartz B, King B, Wisnoski D, Kang J, Eidam P, Votta B, Gough P, Marquis R, Vertin J, Casillas
L (2015) Crystal Structures of Human RIPK2 Kinase Catalytic Domain Complexed With ATP-
Competitive Inhibitors: Foundations for Understanding Inhibitor Selectivity. Bioorganic Medicinal
Chemistry, 23(21): 7000-6
Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, Lich JD, Finger J, Kasparcova V,
Votta B, Ouellette M, King BW, Wisnoski D, Lakdawala AS, DeMartino MP, Casillas LN, Haile
PA, Sehon CA, Marquis RW, Upton J, Daley-Bauer LP, Roback L, Ramia N, Dovey CM, Carette JE,
Chan FK, Bertin J, Gough PJ, Mocarski ES, Kaiser WJ (2014) RIP3 Induces Apoptosis Independent
of Pronecrotic Kinase Activity. Molecular Cell, 56(4): 481-95
Harris P, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti C, Cox J, Dare L, Finger J,
Hoffman S, Kahler K, Lehr R, Lich J, Nagilla R, Nolte R, Ouellette M, Pao C, Schaeffer M,
Smallwood A, Sun H, Swift B, Totoritis R, Ward P, Marquis R, Bertin J, Gough J (2013) Discovery
of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with
Necroptosis. ACS Medicinal Chemistry Letters, 4(12): 1238-43
PRESENTATIONS & POSTERS
Ouellette M. RIPK1 Small Molecule Discovery Case Study. Oral presentation at
GlaxoSmithKline Drug Design & Selection Seminar Series 2016: Collegeville, PA 19426
Ouellette M, Kallal L, Steiginga M, Graybill T, Bandyopadhyay D, Widdowson K, Pope A,
Akabas M. A Novel Yeast Based Assay to Discover Inhibitors of P. falciparum Nucleoside
Transporter ENT1. Poster presented at GSK Sharing Science Day 2015
Cottom J, Ouellette M. Increased HTRF pre-read delay time reduces hit rate by eliminating many e
optical interference compounds. Poster presented at UP Sharing Science Day 2015
Montoute M, Bee T, Ouellette M, Hofmann G, Wu Z, Gore L, Benowitz A, Gilmartin A, Boyer J.
Identification of Novel Hemoglobin-γ Inducers Through a Disease Relevant Phenotypic Screen
With Annotated Compound Library. Poster presented at UP Sharing Science Day 2015
BandyopadhyayD, Ouellette M, Scavello G, ChakravortyS, RamanjuluJ, Martens S.
Enhancing Hit-to-Lead with SAR extracted from Screening Datasets using Scaffold Detection
and R-Group analysis. Poster presented at GSK Science Day 2013
Ouellette M, Cox J, Gao E, Wu Z, Casillas L, Ogden C, Votta B. RIPK2: Discovery in Partner-
Ship with the PRR-DPU. GSK 2013: King of Prussia, PA 19406
Ouellette M. Sequence to Structure – Decoding the DNA Encoded Library. Oral presentation
at GSK Science Forum 2008: King of Prussia, PA 19406
Cowan C, Ouellette M, Payne R, Hudson C, Eckhardt A, Oakley R. Process Improvements in
Cell Delivery for GPCR High Throughput Screening. Oral presentation at Society for
4. Michael T. Ouellette, 619 East Reeceville Rd Downingtown, PA 19335 • (610) 324-0234
michael.t.ouellette@gsk.com
Biomolecular Screening 2004: Orlando, FL 32801
Rhem S, Sherman B, Ouellette M, Cowan C. Comparison of Compound Characterization with
Transfluor and AlphaScreen. Poster presented at Society for Biomolecular Screening 2004:
Orlando, FL 32801
Ouellette M, Rhem S, Sherman B, Geraghty C, Meyers D, Cruickshank R, Cowan C.
Development, Conduct and Results of Two High Throughput Screens Using Transfluor
Technology. Poster